Reference : Strontium Ranelate (Fujisawa/Servier)
Scientific journals : Article
Human health sciences : Public health, health care sciences & services
Human health sciences : Rheumatology
http://hdl.handle.net/2268/87198
Strontium Ranelate (Fujisawa/Servier)
English
Jupsin, Isabelle mailto [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
Collette, Julien mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chimie médicale >]
Henrotin, Yves mailto [Université de Liège - ULg > > Unité de recherche sur l'os et le cartillage (U.R.O.C.) >]
Bruyère, Olivier mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Sarlet, Nathalie [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Apr-2005
Current Opinion in Investigational Drugs (London, England : 2000)
6
4
435-44
Yes (verified by ORBi)
International
1472-4472
[en] Strontium ranelate (PROTELOS), a divalent strontium salt, has been developed and launched by Servier for the treatment of osteoporosis. Fujisawa Pharmaceutical is developing the drug in Japan; in November 2004, phase II Japanese trials were ongoing.
http://hdl.handle.net/2268/87198

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Strontium ranelate Fujisawa-Servier.pdfPublisher postprint2.55 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.